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Abstract
Background: Polyphenols may lower the risk of cardiovascular disease (CVD) and other chronic diseases due to
their antioxidant and anti-inflammatory properties, as well as their beneficial effects on blood pressure, lipids and
insulin resistance. However, no previous epidemiological studies have evaluated the relationship between the intake
of total polyphenols intake and polyphenol subclasses with overall mortality. Our aim was to evaluate whether
polyphenol intake is associated with all-cause mortality in subjects at high cardiovascular risk.
Methods: We used data from the PREDIMED study, a 7,447-participant, parallel-group, randomized, multicenter,
controlled five-year feeding trial aimed at assessing the effects of the Mediterranean Diet in primary prevention of
cardiovascular disease. Polyphenol intake was calculated by matching food consumption data from repeated food
frequency questionnaires (FFQ) with the Phenol-Explorer database on the polyphenol content of each reported
food. Hazard ratios (HR) and 95% confidence intervals (CI) between polyphenol intake and mortality were estimated
using time-dependent Cox proportional hazard models.
Results: Over an average of 4.8 years of follow-up, we observed 327 deaths. After multivariate adjustment, we
found a 37% relative reduction in all-cause mortality comparing the highest versus the lowest quintiles of total
polyphenol intake (hazard ratio (HR)=0.63; 95% CI 0.41 to 0.97; P for trend=0.12). Among the polyphenol subclasses,
stilbenes and lignans were significantly associated with reduced all-cause mortality (HR =0.48; 95% CI 0.25 to 0.91; P for
trend=0.04 and HR=0.60; 95% CI 0.37 to 0.97; P for trend=0.03, respectively), with no significant associations apparent
in the rest (flavonoids or phenolic acids).
Conclusions: Among high-risk subjects, those who reported a high polyphenol intake, especially of stilbenes and
lignans, showed a reduced risk of overall mortality compared to those with lower intakes. These results may be useful
to determine optimal polyphenol intake or specific food sources of polyphenols that may reduce the risk of all-cause
mortality.
Clinical trial registration: ISRCTN35739639.
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Diet and lifestyle are crucial in the prevention of chronic
illnesses and therefore substantially lower all-cause mortal-
ity in most westernized countries. There is evidence that
the Mediterranean diet (MedDiet), a well characterized
dietary pattern, is associated with longevity and improved
quality of life by reducing the risk of the most frequent
chronic diseases such as cardiovascular diseases (CVD),
metabolic syndrome, age-related cognitive impairment, type
2 diabetes mellitus (T2DM), cancer and also all-cause mor-
tality [1,2]. The MedDiet is rich in fruits and vegetables,
olive oil, nuts, legumes, whole-wheat bread and fish, and
wine is consumed in moderate amounts during meals [2].
W i t hr e s p e c tt on u t r i e n t s ,t h eM e d D i e ti sv e r yr i c hi n
mono- and polyunsaturated fatty acids [3] and also in
polyphenols, which are bioactive compounds mainly
found in plant foods and plant-derived beverages such
as coffee, tea and red wine.
Several studies have examined the association between
intake of certain polyphenol subgroups and their sources,
and the incidence of chronic degenerative diseases [4], as
well as their effects on blood pressure, lipid profile, and
endothelial and platelet function [5-7]. If polyphenol
intake does protect against the development of chronic
diseases such as CVD, cancer or T2DM, we hypothe-
sized that a greater consumption of polyphenols would
contribute to lower the risk of all-cause mortality and
provide a greater life expectancy.
To date, the association between specific groups of
polyphenols and mortality has been described [8], but to
our knowledge, neither total polyphenol intake nor that
of the different polyphenol subgroups, have been associ-
ated with all-cause mortality. We therefore embarked on
a study to evaluate the association between the intake of
total polyphenols and polyphenol subgroups and the risk
of overall mortality, using the Phenol-Explorer database
[9] to estimate the polyphenol intake recorded by the
food frequency questionnaires (FFQ) administered yearly
in the PREDIMED (Prevención con Dieta Mediterránea)
trial. These results may be useful to determine optimal
polyphenol intake or specific food sources of polyphenols
that may reduce the risk of all-cause mortality among
subjects at high cardiovascular risk.
Methods
The PREDIMED study
The PREDIMED study was a parallel-group, randomized,
multicenter, controlled feeding trial aimed at assessing the
effects of the MedDiet in the primary prevention of car-
diovascular disease. Details of the recruitment method
and study design have been described elsewhere [10]. The
eligible participants were 7,447 community-dwelling men
(55 to 80 years) and women (60 to 80 years) from Spain,
who had no cardiovascular disease at enrollment but were
at high risk: they had either T2DM or at least three of
the following major risk factors: smoking, hypertension,
dyslipidemia, overweight or obesity, or a family history
of premature coronary heart disease. Starting on 1 October
2003, the eligible participants were randomized in a
1:1:1 ratio to one of three dietary intervention groups:
1) MedDiet supplemented with extra-virgin olive oil
(EVOO), 2) MedDiet supplemented with mixed nuts or
3) control diet (low-fat diet). The trial was stopped after
a median follow-up of 4.8 years due to the benefit of the
MedDiets with respect to major cardiovascular events:
myocardial infarction, stroke or death from cardiovas-
cular causes (analysis performed by the Drug and Safety
Monitoring Board of the trial), compared to a control
low-fat group [2]. All participants provided written in-
formed consent, and the study protocol was approved
by the Institutional Review Boards of the participating
centers (Hospital Clínic of Barcelona (coordinating centre),
Universities of Barcelona, Valencia, Rovira-Virgili, Málaga
and Las Palmas, Municipal Institute for Medical Research,
Primary Care Division of Barcelona and Sevilla, Institute
of Research in Health Sciences (IUNICS) at Palma de
Mallorca, Hospital Txangorritxu of Vitoria, and University
Hospital of Bellvitge) and registered [11].
Study population and characteristics
The present study was conducted as a re-analysis of an
intervention feeding study using polyphenol intake as
the exposure. Data came from all participants of the
PREDIMED trial, but we excluded 247 individuals with
an inadequate FFQ at baseline and 28 with a total energy
intake out of the predefined limits (that is, daily energy
intake <500 or >3,500 for women and <800 or >4,000 kcal/d
for men; n=28) [12]. Therefore, data from 7,172 partici-
pants were available for this analysis.
Participants filled out the following questionnaires at
baseline and yearly thereafter: a validated 14-point score
questionnaire on adherence to the traditional MedDiet
[13], a validated 137-item FFQ [14], and a general ques-
tionnaire which included data on lifestyle habits, concur-
rent diseases and medication used.
Polyphenol intake and dietary assessment
At baseline and yearly thereafter, trained dietitians com-
pleted the validated 137-item FFQ [14] in a face-to-face
interview with the participant. Energy and nutrient in-
take were estimated from the FFQ by multiplying the
frequency of consumption by the average portion size
using Spanish food composition tables.
In a previous study conducted by our group, total poly-
phenol excreted in spot urine samples was validated as
a biomarker of total polyphenol intake from FFQ in a
clinical trial (r=0.48, P <0.01) and in a cross-sectional
study (r=0.26, P=0.04) [15]. The Phenol-Explorer database
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tent in foods. This database included 516 polyphenols con-
tained in 456 foods [16] at the time of our analysis, being
the most complete database currently available for polyphe-
nol content. Correspondence between food items in the
FFQ and the Phenol-Explorer database has been described
previously [17]. Individual polyphenol intake was calculated
by multiplying the content of each polyphenol in a particular
food item (mg/g) by the daily consumption of this food item
(g/day) and then summing the product across all food items.
T o t a lp o l y p h e n o li n t a k ew a st h es u mo fa l li n d i v i d u a lp o l y -
phenol intakes.
Polyphenol and other nutrient intakes were adjusted
for total energy intake because it is associated with disease
risk and is usually proportional to most nutrient intake
[18]. To conduct the analyses, we also used weighted cu-
mulative averages, that is, the polyphenol intake of a given
year was the average between the intake of that year and
the average of the previous years.
Ascertainment of the outcome
Information on mortality was updated yearly by the end-
point adjudication committee, whose members were
unaware of dietary intakes or intervention assignments.
The sources of information were the following: yearly
questionnaires and examinations from all participants,
family physicians, yearly review of medical records and
linkage to the National Death Index. All outcomes were
reported between 1 October 2003 and 1 December 2010.
Statistical analyses
We calculated the weighted cumulative average of poly-
phenol intake at each yearly visit to represent long-term
polyphenol intake. Polyphenols and other food and nu-
trient intake were adjusted for total calories using the
residual method. Non-dietary covariates such as smoking,
body mass index (BMI), physical activity and medication
use were updated yearly.
The baseline characteristics of the 7,172 participants
were distributed by quintiles of total polyphenol intake.
Data were presented as means (±SD) for continuous
variables and frequencies, and percentages for categor-
ical variables. We used one-factor ANOVA or Pearson
chi-squared tests to compare the quantitative or cat-
egorical baseline characteristics of the study participants
across quintiles of baseline polyphenol intake. Person-
time for each participant was calculated as the time
between randomization and the date of death, the date
when completing the last interview, 1 December 2010
or date at death, whichever came first. To assess the risk
of total mortality by quintiles of polyphenol intake,
we ran time-dependent Cox proportional hazard regres-
sions with updated diet and covariates. The referent
group was the lowest quintile of polyphenol intake.
Results are expressed as hazard ratios (HRs) with 95%
confidence intervals (CIs). To show the crude differ-
ences in death rates by groups of polyphenol intake, we
performed a Nelson Aalen survival function, a non-
parametric estimator of the survival function for cen-
sored data.
Moreover, we used likelihood ratio tests of interaction
in stratified analyses to study the possible interactions
among the main risk factors and, as sensitivity analyses,
we estimated the fully adjusted HR, excluding participants
with less than one or two years of follow-up.
Covariates
To take into account the potential differences in risk fac-
tors, all Cox proportional hazard analyses were carried out
with stratification for recruitment center, sex and interven-
tion group. In model 2, we adjusted for sex, age (<60, 60 to
64.9, 65 to 69.9, 70 to 74.9, >/=75 years), smoking status
(never, past and current: cigarettes (<5, 5 to 19, >20 per
day) or cigars and pipes (<3, 3 to 6, >6 per day)), BMI
(<25, 25 to 29.9, or >/=30 Kg/m
2), baseline diabetes, alco-
hol consumption (0, 0.1 to 14.9, 15 to 29.9, >/=30 g/day),
total energy intake (continuous variable), physical activity
(continuous variable), family history of CVD and/or
cancer, aspirin use, antihypertensive drug use, use of
cardiovascular medication, use of oral hypoglycemic
agents, insulin and other medication. In model 3, we
additionally adjusted for intake of protein, saturated fatty
acids, polyunsaturated fatty acids, monounsaturated fatty
acids and cholesterol. We did not include in the model
other variables that did not change the HR by 10% or
more.
Statistical analyses were conducted using SAS soft-
ware, version 9.3 (SAS Institute, Inc., Cary, NC, USA).
All t tests were two-sided and P-values below 0.05 were
considered significant.
Results
The baseline characteristics of participants are shown by
quintiles of energy-adjusted total polyphenol intake in
Table 1. Participants with a greater intake of total polyphe-
nols had a closer adherence to the traditional MedDiet.
They also tended to be more physically active, consume
more alcoholic beverages (mostly wine and beer) and to
have less hypertension. On the contrary, the prevalence of
hypercholesterolemia was higher in those who consumed
more polyphenols at baseline and they were more likely to
be smokers. The groups did not differ in terms of diabetes
status, use of medication and distribution into the three
arms of the trial.
During a mean of 4.8 years of follow-up among 31,068
person-years, the total number of observed deaths was
327. Of these, 131 were due to cancer, 81 were cardio-
vascular and 115 were for other causes. The Nelson
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Q1 Q2 Q3 Q4 Q5 P-value*
(n=1,434) (n=1,435) (n=1,434) (n=1,435) (n=1,434)
Polyphenol intake, mean (cutoff values), mg/d 483 (<642) 674 (642 to 749) 794 (750 to 852) 937 (853 to 995) 1,235 (>995)
Sex, women 836 (58.3) 924 (64.4) 712 (60.8) 803 (56.0) 648 (45.2) <0.0001
Age, mean (SD), y 67.6 (6.2) 67.4 (6.1) 67.4 (5.9) 66.9 (6.0) 66.2 (6.1) <0.0001
BMI, mean (SD), Kg/m
2 30.0 (3.7) 30.3 (3.7) 29.7 (3.5) 29.7 (3.7) 29.6 (3.5) <0.0001
Current smoker 217 (15.1) 210 (14.6) 194 (13.5) 265 (18.5) 317 (22.1) <0.0001
Former smoker 273 (19.0) 263 (18.3) 317 (22.1) 319 (22.2) 413 (28.8)
Sports/exercise, mean (SD), MET-h/d 3.37 (3.56) 3.62 (3.83 3.77 (3.66) 4.05 (4.25) 4.59 (4.54) <0.0001
Diabetes 706 (49.2) 680 (47.4) 712 (49.6) 704 (49.1) 668 (46.6) 0.40
Hypertension 1,230 (85.8) 1,224 (85.3) 1,192 (83.1) 1,166 (81.3) 1,117 (77.9) <0.0001
Hypercholesterolemia 983 (68.6) 1,018 (70.9) 1,053 (73.4) 1,065 (74.2) 1,069 (74.6) 0.001
Hypolipidemic drug use 660 (46.1) 670 (46.7) 712 (49.7) 716 (50.1) 706 (49.5) 0.09
Antihypertensive drug use 1,071 (74.7) 1,095 (76.4) 1,027 (71.7) 1,030 (72.0) 994 (69.7) 0.0004
Cardiovascular drugs use 118 (8.5) 114 (8.2) 120 (8.6) 110 (7.9) 109 (7.9) 0.94
Insulin use 90 (6.3) 87 (6.1) 115 (8.0) 95 (6.6) 99 (6.9) 0.26
Anti-diabetes drug use, other than insulin 463 (32.3) 454 (31.7) 478 (33.4) 465 (32.5) 439 (30.8) 0.65
Aspirin use 302 (21.1) 326 (22.8) 337 (23.5) 318 (22.2) 324 (22.7) 0.63
Int. Group: MedDiet-EVOO 489 (34.1) 506 (35.3) 477 (33.6) 473 (33.0) 517 (36.1) 0.001
Int. Group: MedDiet-nuts 444 (31.0) 467 (32.5) 454 (31.7) 491 (34.2) 519 (36.2)
Mean daily intake:
Total energy intake, mean (SD), Kcal/d 2,397 (642) 2,180 (589) 2,161 (540) 2,229 (563) 2,369 (577) <0.0001
Carbohydrates, mean (SD), g/d 240 (45) 237 (39) 235 (37) 234 (41) 236 (45) 0.006
Protein, mean (SD), g/d 91.9 (15.1) 92.4 (13.8) 92.4 (13.2) 91.5 (13.6) 90.6 (14.9) 0.004
SFA, mean (SD), g/d 26.1 (6.7) 25.4 (5.7) 25.1 (5.3) 24.9 (5.5) 23.5 (5.8) <0.0001
MUFA, mean (SD), g/d 49.0 (12.2) 48.8 (10.6) 48.8 (10.7) 48.7 (11.3) 46.6 (11.2) <0.0001
PUFA, mean (SD), g/d 15.6 (5.8) 15.9 (5.1) 15.8 (5.0) 15.8 (5.2) 15.0 (5.2) <0.0001
Fiber, mean (SD), g/d 21.5 (6.1) 23.9 (6.4) 25.5 (6.7) 26.6 (7.4) 29.4 (8.9) <0.0001
Total cholesterol, mean (SD), mg/d 372 (121) 367 (103) 368 (107) 360 (94) 354 (122) <0.0001
Alcohol, mean (SD), g/d 4.10 (10.9) 6.3 (10.1) 7.6 (10.5) 9.3 (12.8) 14.6 (18.9) <0.0001
Vegetables, mean (SD), g/d 296 (140) 319 (127) 338 (139) 351 (142) 369 (169) <0.0001
Fruits, mean (SD), g/d 240 (133) 319 (145) 364 (157) 404 (172) 521 (245) <0.0001
Legumes, mean (SD), g/d 20.5 (15.3) 20.7 (15.2) 20.3 (10.9) 20.6 (12.4) 20.6 (13.0) 0.93
Dairy products, mean (SD), g/d 398 (226) 391 (216) 389 (208) 380 (219) 353 (217) <0.0001
Cereals, mean (SD), g/d 247 (98) 233 (81) 227 (78) 219 (79) 209 (80) <0.0001
Meat or meat products, mean (SD), g/d 135 (60) 132 (54) 132 (50) 130 (50) 129 (55) 0.03
Fish, mean (SD), g/d 94.3 (53.3) 99.9 (46.8) 101 (51.5) 99.6 (45.0) 102 (49.2) 0.0005
Sugar-sweetened soft drinks, mean (SD), g/d 25.0 (84.3) 19.7 (63.3) 17.8 (55.8) 15.4 (56.1) 12.6 (46.3) <0.0001
Coffee, mean (SD), g/d 25.8 (36.3) 43.6 (40.1) 55.2 (42.9) 70.3 (49.2) 90.1 (63.8) <0.0001
14-points MedDiet questionnaire score, mean (SD) 8.2 (1.9) 8.5 (1.9) 8.7 (1.9) 8.7 (1.9) 9.2 (1.8) <0.0001
Risk factors:
Waist-to-height ratio, mean (SD) 0.64 (0.06) 0.63 (0.07) 0.63 (0.06) 0.62 (0.06) 0.62 (0.06) <0.0001
Systolic BP, mean (SD), mmHg 150 (19) 151 (19) 149 (19) 148 (18) 148 (18) 0.01
Diastolic BP, mean (SD), mmHg 83 (10) 84 (9.8) 82 (9.6) 82 (9.8) 83 (9.6) 0.003
Hearth rate, mean (SD), beats/min 71.7 (11.0) 71.2 (10.9) 70.7 (11.1) 70.0 (10.5) 70.5 (10.5) 0.02
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ferences in death rates by groups of polyphenol intake:
low (<600 mg/d), medium (600 to 750 mg/d) and high
(>750 mg/d).
Table 2 shows Cox Proportional HRs and 95% CI for
total mortality according to quintiles of cumulative in-
take of total polyphenols (according to yearly updated
assessments). After adjusting for all potential confounders
and stratifying by sex, recruitment center and intervention
group, the HR for the highest versus the lowest quintile
was 0.60 (95% CI, 0.39 to 0.91, P-trend=0.07). After fur-
ther adjustment for other dietary confounders, the associ-
ation was not substantially attenuated (HR 0.63, 95% CI,
0.41 to 0.97, P-trend=0.12). We did not see a strong in-
verse linear trend for total polyphenols; instead, the results
suggest a modest threshold above the first quintile of
intake.
In some cases, follow-ups were too short to assess a
mortality endpoint because the ill-health conditions
leading to death may influence diet. Therefore, as sen-
sitivity analyses, we estimated the fully adjusted HR for
the category of the highest total polyphenol intake vs.
the lowest, excluding participants with less than one (31
excluded) or two years of follow-up (75 excluded). In both
cases, the association was robust and remained statistically
significant: HR 0.57, 95% CI, 0.36 to 0.90, P-trend=0.07
and HR 0.49, 95% CI, 0.30 to 0.82, P-trend=0.03,
respectively.
We also conducted stratified analyses (Table 3) by the
other strong predictors of mortality. In multivariable
models, the inverse association between total polyphenol
intake and risk of death, comparing the extreme quintiles,
was stronger among women (HR 0.42, 95% CI, 0.18 to
0.98, P-trend=0.24) than men (HR 0.76, 95% CI, 0.46 to
1.26, P-trend=0.23), although the interaction for sex was
not significant (P-interaction=0.39). We also observed no
significant differences by strata of age (<70 vs >/=70 years).
However, we noted that those who did not drink alcohol
had a stronger inverse association with total polyphenol
intake (HR 0.39, 95% CI, 0.17 to 0.90, P-trend=0.04) than
drinkers (HR 0.99, 95% CI, 0.59 to 1.65, P-trend =0.91),
but the interaction was not significant (P-interaction=
0.16). In other stratified analyses, we observed that the
inverse association did not change substantially among
Table 1 Baseline characteristics according to quintiles of total polyphenol intake at baseline (energy-adjusted)
(Continued)
Glucose (n =4,311), mean (SD), mg/dL 118 (41) 116 (39) 122 (42) 123 (43) 123 (43) 0.0007
Cholesterol (n=4,286), mean (SD), mg/dL 202 (36) 206 (38) 207 (39) 208 (38) 207 (36) 0.003
HDL (n= 4,236), mean (SD), mg/dL 50 (11) 51 (11) 51 (11) 52 (12) 52 (11) 0.007
Triglycerides (n =4,291), mean (SD), mg/dL 130 (67) 133 (74) 137 (79) 130 (63) 138 (80) 0.06
BMI, Body Mass Index; BP, Blood pressure; MedDiet-EVOO, Mediterranean Diet supplemented with extra virgin olive oil; MedDiet-nuts, Mediterranean Diet supplemented
with nuts; SFA, Saturated fatty acids; MUFA, Monounsaturated fatty acids; PUFA, Polyunsaturated fatty acids; HDL, High density lipoprotein.
Data are expressed as No. (%) unless otherwise indicated.
*P-values calculated by analysis of variance or χ
2 tests.
Figure 1 Nelson Aalen estimates of the incidence of death by groups of polyphenol intake.
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active or inactive, or in those with or without T2DM or
hypertension, and none of these interactions were signifi-
cant. Finally, we conducted stratified analyses by interven-
tion groups and found a slightly stronger association
between total polyphenol intake and death in the control
arm of the trial (HR 0.48; CI 0.23 to 0.98; P-trend=0.01)
than in the MedDiet+EVOO arm (HR 0.67; CI 0.31 to
1.46; P-trend=0.68) and the MedDiet+nuts arm (HR
0.68; CI 0.34 to 1.35; P-trend=0.81). However, the inter-
action (P=0.71) was not statistically significant, suggesting
no apparent effect modification.
We further investigated the possible effects of the in-
take of the main polyphenol groups on mortality by any
cause (Table 4). Although no significant associations
were found for flavonoids or phenolic acids, we observed
a 46% reduction in risk of death in participants who
consumed more stilbenes (HR 0.48; CI 0.25 to 0.91;
P-trend= 0.04) and lignans (HR 0.60; CI 0.37 to 0.95;
P-trend= 0.03). For “other polyphenols”,s u c ha st y r o -
sols, alkylphenols, hydroxybenzaldehydes, furanocouma-
rins and hydroxycoumarins, the association was attenuated
after adjustment for other nutrients.
Exploratory analyses (Figure 2) were done for flavo-
noids (see Additional file 1) and phenolic acid subclasses
(see Additional file 2). We found a strong trend towards
a reduction in death risk with a higher intake of isofla-
vones (HR 0.49; CI 0.28 to 0.84; P-trend=0.009). Dihydro-
flavonols were also inversely associated with the risk of
death after multivariable adjustment (HR 0.53; CI 0.28 to
0.99; P-trend=0.05) and the inverse trend was statistically
significant after additional adjustment (P-trend =0.04). No
other subclasses were associated with mortality by any
cause.
Discussion
In this reanalysis of the data of the PREDIMED trial, we
observed a 37% reduction of mortality when comparing
extreme quintiles of total polyphenol intake. The dose-
response trend for the association between total polyphe-
nol intake and all-cause mortality suggested an L-shaped
relationship, with an apparent threshold after the first
quintile of polyphenol intake, instead of an inverse linear
dose-response relationship. Within the polyphenol sub-
classes, stilbenes and lignans were inversely associated
with total mortality.
In stratified analyses we found a stronger association
between total polyphenol intake and mortality risk for
women and for those who did not drink alcohol. Although
the interaction terms were not significant, the observed
trend was suggestive, especially for non-drinkers. The re-
lationship between alcohol intake and polyphenols should
be the main focus of future studies.
To our knowledge, though previous studies have in-
vestigated the association between intake of specific
groups of polyphenols and mortality, this is the first
study to investigate the association between total poly-
phenol intake, as well as that of all polyphenol sub-
groups with all-cause mortality. In addition, we should
acknowledge that the effect of polyphenols and polyphenol-
rich foods on chronic degenerative diseases and clinical
biomarkers has been broadly studied [19-24]. Previous
studies have analyzed the association between polyphenols
f r o mw i n e ,t e a ,c h o c o l a t e ,b e r r i e s ,s o ya n do l i v eo i lw i t h
several chronic degenerative disease risk or mortality
risk [6,25-29]. The reported inverse association, specif-
ically for olive oil and red wine, is consistent with the
inverse association we found for stilbenes and lignans
[29-31]. The suggestion of an inverse association that
we found for several flavonoid compounds is also con-
sistent with previous studies of berries, dark chocolate
and soy [6,25,26]. In many of these previously studied
populations, intake of any one polyphenol-rich food was
not great enough to reduce mortality, but in our study
total polyphenol intake was a wider range, coming from
several food sources.
Table 2 Cox proportional hazard ratios for total mortality according to quintiles of cumulative total polyphenol intake
Quintiles of cumulative intake of total polyphenols, mg/d
Q1 (535) Q2 (700) Q3 (800) Q4 (917) Q5 (1170) P-trend
No. of deaths 88 62 52 63 62
No. of person-years 5,505 6,599 6,767 6,559 5,638
Age- and sex-adjusted HR (95% CI)
* 1.00 0.65 (0.44 to 0.95) 0.55 (0.37 to 0.82) 0.73 (0.50 to 1.06) 0.66 (0.44 to 0.98) 0.12
Multivariable-adjusted HR (95% CI)
† 1.00 0.68 (0.46 to 1.01) 0.60 (0.39 to 0.90) 0.75 (0.51 to 1.12) 0.60 (0.39 to 0.91) 0.07
Additionally adjusted HR (95% CI)
‡ 1.00 0.71 (0.48 to 1.05) 0.62 (0.41 to 0.95) 0.79 (0.53 to 1.17) 0.63 (0.41 to 0.97) 0.12
HR, Hazard ratio; CI, Confidence interval.
*Analyses were stratified by sex, recruitment center and intervention group.
†The multivariable HR has been additionally adjusted for age (<60, 60 to 64.9, 65 to 69.9, 70 to 74.9, >/=75 years), smoking (never, past and current: cigarettes
(<5, 5 to 19, >20 per day) or cigars and pipes (<3, 3 to 6, >6 per day)), BMI (<25, 25 to 29.9, or >/=30 Kg/m
2), baseline diabetes, alcohol (0, 0.1 to 14.9, 15 to
29.9, >/=30 g/day), total energy intake (continuous variable), physical activity (continuous variable), family history of CVD or cancer, aspirin use, antihypertensive
drug use, use of cardiovascular medication, use of oral hypoglycaemic agents, insulin, other medication.
‡This model has been additionally adjusted for intake of protein, saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids and cholesterol
(all as continuous variables).
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among 40,530 healthy Japanese adults and reported that
green tea consumption, a polyphenol-rich beverage,
was inversely associated with cardiovascular diseases
and all-cause mortality, butn o tw i t hm o r t a l i t yd u et o
cancer [27]. Other studies have also found an inverse
association between polyphenol consumption and CVD
and CVD-related mortality [20,25,26,32]. Indeed, it has
been demonstrated that some polyphenols and their
metabolites exert anti-atherosclerotic effects, improve
endothelial function and antioxidant status, increase ni-
tric oxide release, and modulate inflammation and lipid
metabolism [5,21,25,33-35].
Polyphenols can also act as chemopreventive agents.
For example, resveratrol is a well-known stilbene, mostly
found in red wine and grapes, with several health benefits,
including inhibition of tumorgenesis [8,36,37]. In vitro and
in vivo studies have shown that epigallocatechin-3-gallate,
the major polyphenol of green tea, has anti-carcinogenic
effects, such as inhibition of growth proliferation, in-
duction of apoptosis and phase II detoxifying enzymes,
and reduction of oxidative damage to DNA [36-38].
Xanthohumol, quercetin, curcumin and genistein are
other examples of polyphenols that have shown anti-
carcinogenic properties due to their capacity to inhibit
tumor growth [8,22,37,38].
Available evidence supports that dietary modifications
are able to reduce the risk of T2DM, another highly
prevalent chronic disease. Wedick et al. found that antho-
cyanins were inversely associated with the risk of T2DM
Table 3 HR for total mortality according to quintiles of total polyphenol intake (stratified by risk factors)
Risk factor No. of deaths No. of person-years Multivariable-adjusted HR
(95% CI), Quintile 5 vs. 1
*
P-trend P-interaction
Sex
Men 203 13,317 0.76 (0.46 to 1.26) 0.23 0.39
Women 124 17,751 0.42 (0.18 to 0.98) 0.24
Age, y
<70 142 21,483 0.58 (0.31 to 1.08) 0.21 0.73
≥70 185 9,585 0.70 (0.39 to 1.24) 0.34
Alcohol intake
Nondrinkers 133 12,510 0.39 (0.17 to 0.90) 0.04 0.16
Drinkers 194 18,558 0.99 (0.59 to 1.65) 0.91
Smoking
Never 144 19,520 0.64 (0.31 to 1.32) 0.47 0.93
Former 111 7,465 0.52 (0.25 to 1.07) 0.29
Current 72 4,083 0.71 (0.29 to 1.75) 0.21
Physical activity
Less than median 203 16,224 0.57 (0.32 to 1.02) 0.17 0.43
More than median 124 14,844 0.77 (0.41 to 1.44) 0.73
Hypertension
Yes 184 12,080 0.63 (0.36 to 1.10) 0.24 0.21
No 134 17,721 0.82 (0.44 to 1.55) 0.76
Diabetes mellitus
Yes 205 15,345 0.79 (0.47 to 1.33) 0.92 0.52
No 122 15,723 0.60 (0.31 to 1.17) 0.09
Intervention group
MedDiet-EVOO 113 11,478 0.67 (0.31 to 1.46) 0.68 0.71
MedDiet-Nuts 108 10,134 0.68 (0.34 to 1.35) 0.81
Control Diet 106 9,456 0.48 (0.23 to 0.98) 0.01
HR, Hazard ratio; CI, Confidence interval; MedDiet-EVOO, Mediterranean Diet supplemented with extra virgin olive oil; MedDiet-nuts, Mediterranean Diet
supplemented with nuts.
*The multivariable HR has been additionally adjusted for age (<60, 60to 4.9, 65 to 69.9, 70 to 74.9, >/=75 years), smoking (never, past and current: cigarettes
(<5, 5 to 19, >20 per day) or cigars and pipes (<3, 3 to 6, >6 per day)), BMI (<25, 25 to 29.9, or >/=30 Kg/m
2), baseline diabetes, alcohol (0, 0.1 to 14.9, 15 to
29.9, >/=30 g/day), total energy intake (continuous variable), physical activity (continuous variable), family history of CVD or cancer, aspirin use, antihypertensive
drug use, use of cardiovascular medication, use of oral hypoglycemic agents, insulin, other medication. Analyses were stratified by sex, recruitment center and
intervention group.
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et al. found similar associations for blueberries, grapes
and apples [39,40]. Finally, polyphenols have been pro-
posed as promising phytochemicals for the treatment
and prevention of neurogenerative diseases such as
Alzheimer’s disease, Parkinson’s disease and other neuro-
logical disorders [29,41].
All of this evidence from chronic disease studies sup-
ports the hypothesis that greater polyphenol intake, and
the many polyphenol subclasses this represents, serves
to extend the life span through multifactorial etiological
pathways.
Our study has some limitations. First, we controlled
for several confounders in multivariate models, but other
unknown or unmeasured confounders may exist. How-
ever, if this were the case, we would expect relative risks
for all subclasses to be equally over or underestimated and
that was not the case. Second, the number of cases of
cause-specific deaths was too low to estimate individual
relative risks. Others have found the benefits of specific
Table 4 Relationship between mortality and intake of the main polyphenol groups (in quintiles)
Main groups Q1 Q2 Q3 Q4 Q5 P-trend
Flavonoids (mg/d) 273 362 431 512 670
No. of deaths 76 73 42 69 67
No. of person-years 4,890 6,599 6,755 6,867 5,957
Age- and sex-adjusted HR (95% CI)
* 1.00 0.76 (0.52 to 1.10)
* 0.54 (0.36 to 0.81) 0.72 (0.49 to 1.05) 0.70 (0.47 to 1.05) 0.23
Multivariable-adjusted HR (95% CI)
† 1.00 0.92 (0.62 to 1.34) 0.69 (0.45 to 1.07) 0.92 (0.62 to 1.36) 0.83 (0.55 to 1.27) 0.70
Additionally adjusted HR (95% CI)
‡ 1.00 0.96 (0.65 to 1.41) 0.75 (0.48 to 1.16) 0.99 (0.66 to 1.47) 0.89 (0.58 to 1.36) 0.95
Phenolic acids (mg/d) 159 229 279 345 453
No. of deaths 80 58 62 69 58
No. of person-years 5,928 6,662 6,716 6,615 5,147
Age- and sex-adjusted HR (95% CI)
* 1.00 0.95 (0.65 to 1.39) 0.78 (0.53 to 1.16) 1.01 (0.70 to 1.47) 0.95 (0.63 to 1.42) 0.64
Multivariable-adjusted HR (95% CI)
† 1.00 0.94 (0.64 to 1.39) 0.82 (0.55 to 1.23) 1.07 (0.72 to 1.58) 0.79 (0.51 to 1.22) 0.25
Additionally adjusted HR (95% CI)
‡ 1.00 0.89 (0.60 to 1.31) 0.77 (0.52 to 1.16) 1.01 (0.68 to 1.50) 0.75 (0.49 to 1.16) 0.20
Stilbenes (mg/d) 0 0.48 1.04 2.04 5.75
No. of deaths 69 64 47 74 73
No. of person-years 5,191 6,547 6,840 6,527 5,963
Age- and sex-adjusted HR (95% CI)
* 1.00 0.71 (0.47 to 1.05) 0.66 (0.44 to 0.98) 0.81 (0.56 to 1.18) 0.73 (0.56 to 1.18) 0.44
Multivariable-adjusted HR (95% CI)
† 1.00 0.61 (0.33 to 1.11) 0.53 (0.28 to 0.99) 0.68 (0.38 to 1.22) 0.42 (0.22 to 0.81) 0.04
Additionally adjusted HR (95% CI)
‡ 1.00 0.69 (0.38 to 1.27) 0.62 (0.33 to 1.16) 0.78 (0.43 to 1.40) 0.48 (0.25 to 0.91) 0.04
Lignans (mg/d) 0.44 0.57 0.67 0.77 0.94
No. of deaths 76 72 57 55 67
No. of person-years 4,457 6,002 6,737 7,146 6,726
Age- and sex-adjusted HR (95% CI)
* 1.00 0.66 (0.46 to 0.96) 0.58 (0.39 to 0.85) 0.58 (0.39 to 0.87) 0.54 (0.35 to 0.82) 0.002
Multivariable-adjusted HR (95% CI)
† 1.00 0.65 (0.44 to 0.99) 0.56 (0.38 to 0.84) 0.56 (0.36 to 0.84) 0.51 (0.32 to 0.79) 0.001
Additionally adjusted HR (95% CI)
‡ 1.00 0.68 (0.46 to 1.00) 0.60 (0.40 to 0.92) 0.62 (0.39 to 0.98) 0.60 (0.37 to 0.97) 0.03
Others (mg/d) 37 53 66 82 113
No. of deaths 77 65 72 60 53
No. of person-years 4,604 6,442 7,320 6,777 5,925
Age- and sex-adjusted HR (95% CI)
* 1.00 0.76 (0.52 to 1.11) 0.78 (0.54 to 1.13) 0.68 (0.46 to 1.01) 0.64 (0.42 to 0.96) 0.04
Multivariable-adjusted HR (95% CI)
† 1.00 0.76 (0.51 to 1.13) 0.80 (0.54 to 1.18) 0.67 (0.45 to 1.02) 0.61 (0.40 to 0.93) 0.03
Additionally adjusted HR (95% CI)
‡ 1.00 0.82 (0.55 to 1.22) 0.86 (0.58 to 1.27) 0.76 (0.50 to 1.16) 0.70 (0.46 to 1.09) 0.13
HR, Hazard Ratio; CI, confidence interval.
*Analyses were stratified by sex, recruitment center and intervention group.
†The multivariable HR has been additionally adjusted for age (<60, 60 to 64.9, 65 to 69.9, 70 to 74.9, >/=75 years), smoking (never, past and current: cigarettes
(<5, 5 to 19, >20 per day) or cigars and pipes (<3, 3 to 6, >6 per day)), BMI (<25, 25 to 29.9, or >/=30 Kg/m
2), baseline diabetes, alcohol (0, 0.1 to 14.9, 15 to
29.9, >/=30 g/day), total energy intake (continuous variable), physical activity (continuous variable), family history of CVD or cancer, aspirin use, antihypertensive
drug use, use of cardiovascular medication, use of oral hypoglycaemic agents, insulin, other medication.
‡This model has been additionally adjusted for intake of protein, saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids and cholesterol
(all as continuous variables).
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spiratory disease. Future work in this area should include
larger studies with estimates of total polyphenol intake.
Third, there were limitations with respect to the estima-
tion of polyphenol intake because data were indirectly
derived from the FFQs. Although urinary excretion of
polyphenols was validated as a biomarker of total polyphe-
nol from the FFQ in two different studies, the values of r
were relatively low. The absence of information about
some foods in the FFQ could lead to an underestimation
of the intake. Moreover, the study did not take into
account the bioavailability of these molecules. Finally,
these results might be valid only for elderly people at
high cardiovascular risk and other studies are needed to
generalize the conclusions to other populations.
On the other hand, the main strengths of the study are
the prospective design, the large sample size with a rela-
tively long-term follow-up, and comprehensive data on
risk factors and confounders. Very importantly, our use
of the cumulative average of polyphenol intake across
yearly repeated measurements of diet is considered as the
best approach to reduce measurement error in nutritional
epidemiology [42] and allowed changes in the diet due
to the intervention or other secular trends in intake in
Spain to be controlled. We also used the most com-
prehensive polyphenol database currently available
(Phenol-explorer database), which allowed risk estima-
tion related not only to intake of total polyphenol but
also all the polyphenol subgroups and subclasses. This
comprehensive analysis differentiates our paper from
previous related studies.
Conclusions
We found an apparent inverse association between total
polyphenol intake and the risk of overall mortality, which
was independent of other dietary and non-dietary risk fac-
tors. This may be helpful in establishing future daily poly-
phenol intake recommendations. However, more studies
are needed to definitively clarify the benefits deriving from
long-term consumption of polyphenol-rich foods.
Other PREDIMED Investigators
Other contributors list (Additional file 3).
Figure 2 Hazard ratios (95% CI) of total mortality for the highest vs. lowest quintiles of polyphenol intake.
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